arrow
A

Alexandre Prat

centre de recherche du chum
H指数:83
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Periventricular gradient pathology is linked to ependymal reactivity and cell adhesion disruption in multiple sclerosis

室管膜周围梯度病理与多发性硬化症中的室管膜细胞反应性和细胞粘附破坏有关

2026-10-150
PRE
Antigen presentation by CD40+MHC-II+ astrocytes promotes CNS autoimmunity

CD40和MHC-II阳性的星形胶质细胞介导的抗原呈递促进中枢神经系统自身免疫反应

Nature
IF48.5
2026-08-050
PRE
Causal effects of multiple sclerosis therapies in left-truncated registry data

多发性硬化疗法在左截断登记数据中的因果效应

2026-07-210
PRE
Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria

2024年麦唐纳诊断标准后多发性硬化的挑战与未来方向

2026-07-090
PRE
Widespread gene-environment interactions shape the immune response to SARS-CoV-2 infection in hospitalized COVID-19 patients

广泛存在的基因-环境相互作用塑造了住院COVID-19患者对SARS-CoV-2感染的免疫反应

2026-04-280
OAAI
Oxidized phosphatidylcholines deposition drives chronic neurodegeneration in a mouse model of progressive multiple sclerosis via IL-1β signaling

氧化磷脂酰胆碱沉积通过IL-1β信号通路驱动渐进性多发性硬化症小鼠模型中的慢性神经退行性变

2025-12-010
PRE
Bruton’s tyrosine kinase inhibitors rescue neuronal impairment caused by B cell–mediated lymphotoxin-α release

布鲁顿酪氨酸激酶抑制剂可挽救由B细胞介导的淋巴毒素-α释放引起的神经元损伤

2025-10-290
PRE
Disease course after pregnancy in women with progressive multiple sclerosis symptoms

妊娠后进展性多发性硬化症状女性的疾病病程

2025-09-200
OA
Author Correction: Disease-associated astrocyte epigenetic memory promotes CNS pathology

作者更正: 疾病相关星形胶质细胞表观遗传记忆促进CNS病理

Nature
IF48.5
2025-08-260
OA
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

克拉屈滨在复发型多发性硬化中的临床和机制性作用:MAGNIFY-MS研究2年结果

2025-07-310
OA
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

基于真实世界常规临床数据的个性化联邦学习在预测多发性硬化致残进展中的应用

2025-07-240
OAAI
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

研究总结:接受克拉屈滨片治疗复发型多发性硬化患者的血液生物标志物动态变化:MAGNIFY-MS研究2年结果

2025-07-040
OAAI
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

复发缓解型多发性硬化中与复发活动无关的进展标准化定义(PIRA)

2025-06-010
PRE
Explainable time-to-progression predictions in multiple sclerosis

多发性硬化症可解释的进展时间预测

2025-05-010
PRE
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

克拉屈滨片治疗复发性多发性硬化症患者的血液生物标志物动态: 2年MAGNIFY-MS研究结果

2025-02-030
OAAI
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

一年治疗反应预测复发缓解型多发性硬化患者后续5年的疾病进程

2025-02-010
OAAI
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network

原发性进行性MS患者亚类的疾病改善治疗和残疾进展: 来自大MS数据网络的结果

2024-12-060
OAAI